A blood test being developed by Roche and Eli Lilly that could help diagnose patients with Alzheimer’s disease more quickly has been awarded breakthrough status by the FDA
In another inflection point for the psychedelic medicines category, Mind Medicine (MindMed) has claimed breakthrough status from the FDA for its LSD-based candidate MM120
The booming interest in new targeted therapies represents a changing of the guard in cancer treatment, from the former one-size-fits-all approach to a more personalised methodology.